Your session is about to expire
← Back to Search
Machine Learning Technology
Device Arm for COVID-19 (AIDI Trial)
N/A
Waitlist Available
Led By Sujith Shetty, MD
Research Sponsored by AIDAR Health, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male or female 18 years of age or older
Unvaccinated individuals, or individuals who have received only 1 dose of an mRNA vaccine
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 60 days
Awards & highlights
AIDI Trial Summary
The AIDI study has to phases. It's purpose is to capture vital signs using a non-invasive, hand-held, home monitoring device (MouthLab Device) from individuals with COVID-19 or who test positive for SARS-CoV-2 (Phase I) and use an algorithm-based approach to identify individuals at risk of clinical decompensation (Phase II). Up to 500 unvaccinated and partially vaccinated subjects will be included (up to 100 in Phase I and up to 400 in Phase II).
Eligible Conditions
- COVID-19
AIDI Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAIDI Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 60 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 60 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
AIDI evaluation
Collect trends in physiological vital signs and symptom burden to identify individuals who are at risk of clinical decompensation
Secondary outcome measures
Evaluate any short-term changes in vital signs among patients with underlying comorbid conditions
Usability of MouthLab device
AIDI Trial Design
1Treatment groups
Experimental Treatment
Group I: Device ArmExperimental Treatment1 Intervention
Participants will use the MouthLab device for monitoring their vital signs
Find a Location
Who is running the clinical trial?
AIDAR Health, Inc.Lead Sponsor
1 Previous Clinical Trials
204 Total Patients Enrolled
1 Trials studying COVID-19
204 Patients Enrolled for COVID-19
MAXIS, LLCUNKNOWN
1 Previous Clinical Trials
5 Total Patients Enrolled
Sujith Shetty, MDPrincipal InvestigatorMAXIS, LLC
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger